EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

An immunoregulatory amphipathic peptide derived from Fasciola hepatica helminth defense molecule ( FhHDM ‐1. C2 ) exhibits potent biotherapeutic activity in a murine model of multiple sclerosis

Richard Lalor iD, Akane Tanaka iD, Jenna Shiels iD, Aakanksha Dixit iD, Sabine Hoadley, Eloïse Dufourd, Siobhan Hamon, Joyce To iD, Clifford C Taggart iD, Sinead Weldon iD, Bronwyn O'Brien iD, Judith Greer iD und 2 weitere

The FASEB Journal · 28.02.2025 · 39 (4)

DOI: 10.1096/fj.202400793rr ↗

Kurz gefasst

Fachartikel in der Zeitschrift The FASEB Journal, online erschienen am 14.02.2025. Verfasst von Richard Lalor und 13 weiteren Autor:innen. Beteiligte Einrichtung: Molecular Parasitology Laboratory, Centre of one Health (COH) and Ryan Institute, School of Natural Science, University of Galway, Galway, Ireland. Hauptthemen laut MEDLINE: Fasciola hepatica, Helminth Proteins, Multiple Sclerosis, Encephalomyelitis, Autoimmune, Experimental. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Health and Medical Research Council Australia, Science Foundation Ireland.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The helminth defense molecules (HDM) are a family of immune regulatory peptides exclusively expressed by trematode worms. We have previously demonstrated that in vivo FhHDM‐1, the archetypal member of the HDMs, regulated macrophage responses to inflammatory ligands, thereby ameliorating the progression of immune‐mediated tissue damage in several murine models of inflammatory disease. Accordingly, we postulated that an understanding of the structure–function relationship of the HDMs would facilitate the identification of the minimal bioactive peptide, which would represent a more synthesizable, cost‐effective, potent biotherapeutic. Thus, using a combination of bioinformatics, structural analyses, and cellular assays we discovered a 40 amino acid peptide derivative termed FhHDM‐1.C2. This peptide contains a 12 amino acid motif at its N‐terminus, which facilitates cellular interaction and uptake, and an amphipathic α‐helix within the C‐terminus, which is necessary for lysosomal vATPase inhibitory activity, with both regions linked by a short unstructured segment. The FhHDM‐1.C2 peptide exhibits enhanced regulation of macrophage function, compared with the full‐length FhHDM‐1, and potent prevention of the progression of relapsing–remitting‐experimental autoimmune encephalomyelitis (EAE) when administered prophylactically or therapeutically. The protective effect of FhHDM‐1.C2 is not associated with global immune suppression, which places the HDMs peptides as an improved class of biotherapeutics for the treatment of inflammatory diseases. Comparing the HDMs from several zoonotic trematodes revealed a similar capacity for immune regulation. These important new advances into the structure–function relationship of the lead HDM peptide, FhHDM‐1, encourage further prospecting and screening of the broader trematode family of peptides for the discovery of novel and potent immune‐biotherapeutics.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Fasciola hepaticaHelminth ProteinsMultiple SclerosisEncephalomyelitis, Autoimmune, ExperimentalPeptidesAnimalsMiceDisease Models, AnimalHumansFemaleMacrophagesMice, Inbred C57BLAmino Acid Sequence

Stichwörter der Autor:innen

Fasciola hepaticaexperimental autoimmune encephalomyelitishelminth defense moleculeimmune regulationmacrophage

Substanzen

Helminth ProteinsPeptides

Autor:innen und Institutionen

  • Molecular Parasitology Laboratory, Centre of one Health (COH) and Ryan Institute, School of Natural Science, University of Galway, Galway, Ireland.
  • School of Life Sciences, University of Technology Sydney, Sydney, Australia.
  • Wellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, Belfast, UK.
  • UQ Centre for Clinical Research, The University of Queensland, Brisbane, Queensland, Australia.

ORCID-Profile: Richard Lalor, Akane Tanaka, Jenna Shiels, Aakanksha Dixit, Joyce To, Clifford C Taggart, Sinead Weldon, Bronwyn O'Brien, Judith Greer, Sheila Donnelly

Förderung

  • National Health and Medical Research Council Australia
  • Science Foundation Ireland

Zitieren

APA

Lalor, R., Tanaka, A., Shiels, J., Dixit, A., Hoadley, S., Dufourd, E., Hamon, S., To, J., Taggart, C. C., Weldon, S., O'Brien, B., Greer, J., Dalton, J. P., & Donnelly, S. (2025). An immunoregulatory amphipathic peptide derived from Fasciola hepatica helminth defense molecule ( FhHDM ‐1. C2 ) exhibits potent biotherapeutic activity in a murine model of multiple sclerosis. The FASEB Journal, 39(4). https://doi.org/10.1096/fj.202400793rr

Vancouver

Lalor R, Tanaka A, Shiels J, Dixit A, Hoadley S, Dufourd E, et al. An immunoregulatory amphipathic peptide derived from Fasciola hepatica helminth defense molecule ( FhHDM ‐1. C2 ) exhibits potent biotherapeutic activity in a murine model of multiple sclerosis. The FASEB Journal. 2025;39(4). doi:10.1096/fj.202400793rr

BibTeX
@article{Lalor2025,
  author = {Lalor, Richard and Tanaka, Akane and Shiels, Jenna and Dixit, Aakanksha and Hoadley, Sabine and Dufourd, Eloïse and Hamon, Siobhan and To, Joyce and Taggart, Clifford C and Weldon, Sinead and O'Brien, Bronwyn and Greer, Judith and Dalton, John P and Donnelly, Sheila},
  title = {An immunoregulatory amphipathic peptide derived from Fasciola hepatica helminth defense molecule ( FhHDM ‐1. C2 ) exhibits potent biotherapeutic activity in a murine model of multiple sclerosis},
  journal = {The FASEB Journal},
  year = {2025},
  volume = {39},
  number = {4},
  doi = {10.1096/fj.202400793rr}
}
Kostenlos starten →